Moreno Evelyn V cut its stake in Edwards Lifesciences Corp (NYSE:EW) by 55.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,250 shares of the medical research company’s stock after selling 4,000 shares during the quarter. Moreno Evelyn V’s holdings in Edwards Lifesciences were worth $600,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Dimensional Fund Advisors LP boosted its stake in shares of Edwards Lifesciences by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 601,150 shares of the medical research company’s stock worth $92,071,000 after acquiring an additional 22,354 shares in the last quarter. Geode Capital Management LLC lifted its stake in Edwards Lifesciences by 7.4% in the 4th quarter. Geode Capital Management LLC now owns 2,942,494 shares of the medical research company’s stock valued at $449,976,000 after buying an additional 202,248 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Edwards Lifesciences in the 1st quarter valued at approximately $843,000. First Manhattan Co. lifted its stake in Edwards Lifesciences by 630.3% in the 1st quarter. First Manhattan Co. now owns 2,337 shares of the medical research company’s stock valued at $447,000 after buying an additional 2,017 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in Edwards Lifesciences in the 1st quarter valued at approximately $296,000. 82.43% of the stock is currently owned by institutional investors.
A number of equities research analysts recently issued reports on the company. Raymond James upped their target price on Edwards Lifesciences from $200.00 to $232.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Bank of America reaffirmed a “buy” rating and issued a $225.00 target price (up previously from $215.00) on shares of Edwards Lifesciences in a research note on Wednesday, July 24th. Morgan Stanley upped their target price on Edwards Lifesciences from $210.00 to $228.00 and gave the company an “overweight” rating in a research note on Wednesday, July 24th. Wells Fargo & Co upped their target price on Edwards Lifesciences from $207.00 to $220.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Finally, Citigroup set a $159.00 target price on Edwards Lifesciences and gave the company a “sell” rating in a research note on Friday, July 26th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $204.74.
EW traded up $2.73 during trading on Thursday, hitting $216.24. The company’s stock had a trading volume of 29,039 shares, compared to its average volume of 1,186,828. The business has a 50 day simple moving average of $200.64. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.48 and a current ratio of 3.38. The stock has a market cap of $44.90 billion, a PE ratio of 45.93, a PEG ratio of 2.72 and a beta of 0.87. Edwards Lifesciences Corp has a twelve month low of $134.53 and a twelve month high of $219.71.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.33 by $0.05. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. Edwards Lifesciences had a return on equity of 31.25% and a net margin of 18.29%. Edwards Lifesciences’s revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.24 EPS. As a group, research analysts expect that Edwards Lifesciences Corp will post 5.34 EPS for the current year.
In other news, CEO Michael A. Mussallem sold 22,850 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $184.27, for a total transaction of $4,210,569.50. Following the completion of the sale, the chief executive officer now directly owns 95,770 shares in the company, valued at approximately $17,647,537.90. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,369 shares of the company’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $175.06, for a total value of $939,897.14. Following the sale, the vice president now owns 26,043 shares of the company’s stock, valued at $4,559,087.58. The disclosure for this sale can be found here. Insiders sold a total of 142,948 shares of company stock valued at $27,936,332 over the last quarter. 1.63% of the stock is currently owned by insiders.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Article: When can a hold rating present a buying opportunity?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.